University of California Berkeley
seal E. O. Lawrence Berkeley National
Laboratory seal
The
Carcinogenic Potency Project

Chloroprene (>96% chloroprene) (CAS 126-99-8)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
kid lun orc thy kid mgl orc thy hag kid lun sto vsc ezy hag liv lun mgl per sto sub vsc 12.5m 8.17m

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   ezy = ear/Zymbal’s gland. hag = harderian gland. kid = kidney. liv = liver. lun = lung. mgl = mammary gland. orc = oral cavity (includes tissues of the mouth, oropharynx, pharynx, and larynx). per = peritoneal cavity. sto = stomach. sub = subcutaneous tissue. thy = thyroid gland. vsc = vascular system. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Chloroprene (>96% chloroprene): All Experiments and Citations in CPDB
The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.
Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.
See Guide to reading the plot for details on each field, using an example of one experiment.
See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

CHLOROPRENE (>96% CHLOROPRENE) 126-99-8 1442 M f b6c inh 24m24 TR467 : 0 14.6mg 36.4mg 91.1mg MXB MXB 4.00mg Z P<.0005 2.58mg 6.74mg 28/50 43/50 47/50 (48/50) ---:hem,hes; for:sqc,sqp; hag:ade,car; liv:hpa, hpc; lun:a/a,a/c; mey:sar; mgl:ade,car; sub:sar; zym:car. C lun MXA 5.36mg Z P<.0005 c 3.45mg 8.68mg 4/50 28/50 34/50 (42/50) lun:a/a,a/c. liv MXA 7.07mg Z P<.0005 c 4.03mg 15.4mg 20/50 26/50 20/50 (30/50) liv:hpa,hpc. lun a/a 8.65mg Z P<.0005 c 5.29mg 14.7mg 2/50 16/50 29/50 (26/50) lun a/c 14.6mg * P<.0005 c 9.17mg 24.6mg 2/50 14/50 16/50 28/50 liv hpc 15.2mg Z P<.0005 c 7.94mg 35.2mg 4/50 11/50 14/50 (19/50) liv hpa 19.8mg * P<.0005 10.5mg 51.3mg 17/50 19/50 11/50 16/50 S --- MXA 21.5mg Z P<.0005 c 10.6mg 52.2mg 4/50 6/50 18/50 (8/50) ---:hem,hes. --- hes 22.2mg Z P<.0005 c 10.8mg 55.9mg 4/50 6/50 17/50 (5/50) mey MXA 25.9mg Z P<.0005 12.7mg 53.4mg 0/50 4/50 15/50 (5/50) mey:hem,hes. S sub sar 28.9mg * P<.0005 c 17.1mg 49.5mg 0/50 11/50 11/50 18/50 mey hes 32.2mg Z P<.0005 15.5mg 67.1mg 0/50 4/50 13/50 (4/50) S mey sar 40.0mg Z P<.0005 c 17.5mg 98.8mg 0/50 4/50 8/50 (3/50) hag MXA 55.2mg * P<.0005 c 22.6mg 208.mg 2/50 5/50 3/50 9/50 hag:ade,car. hag ade 61.3mg * P<.0005 c 24.1mg 231.mg 1/50 3/50 3/50 8/50 mgl MXA 65.6mg * P<.0005 c 29.4mg 199.mg 3/50 5/50 8/50 12/50 mgl:ade,car. pit pda 68.1mg * P<.006 26.0mg 1.13gm 4/50 6/50 4/50 4/50 S mgl car 75.3mg * P<.0005 c 32.9mg 233.mg 3/50 4/50 7/50 12/50 --- hem 134.mg * P<.0005 c 38.8mg 793.mg 0/50 0/50 2/50 3/50 for MXA 332.mg * P<.01 c 74.2mg 65.9gm 1/50 0/50 0/50 4/50 for:sqc,sqp. zym car 864.mg * P<.01 c 259.mg 68.6gm 0/50 0/50 0/50 3/50 ute esp 133.mg * P<.04 38.3mg n.s.s. 2/50 4/50 2/50 3/50 S TBA MXB 3.92mg Z P<.0005 2.54mg 6.62mg 34/50 47/50 50/50 (48/50) liv MXB 7.07mg Z P<.0005 4.03mg 15.4mg 20/50 26/50 20/50 (30/50) liv:hpa,hpb,hpc. lun MXB 5.36mg Z P<.0005 3.45mg 8.68mg 4/50 28/50 34/50 (42/50) lun:a/a,a/c. 1443 M m b6c inh 24m24 TR467 : 0 12.1mg 30.4mg 75.9mg MXB MXB 8.68mg Z P<.0005 5.45mg 17.3mg 16/50 33/50 44/50 (48/50) ---:hem,hes; for:sqc,sqp; hag:ade,anb,car; lun: a/a,a/c. C lun MXA 17.2mg * P<.0005 c 11.0mg 31.9mg 13/50 28/50 36/50 43/50 lun:a/a,a/c. --- MXA 17.9mg Z P<.0005 c 11.1mg 35.5mg 3/50 14/50 23/50 (21/50) ---:hem,hes. --- hes 19.1mg Z P<.0005 c 11.7mg 39.0mg 3/50 13/50 22/50 (19/50) liv MXA 19.5mg Z P<.0005 10.4mg 79.1mg 24/50 29/50 39/50 (34/50) liv:hpb,hpc. S --- MXA 21.3mg Z P<.0005 c 13.2mg 41.6mg 1/50 12/50 18/50 (17/50) ---:hem,hes. liv hpc 21.6mg Z P<.002 11.1mg 112.mg 24/50 28/50 37/50 (33/50) S --- hes 23.8mg Z P<.0005 c 14.3mg 49.6mg 1/50 11/50 16/50 (15/50) lun a/c 26.4mg * P<.0005 c 16.8mg 50.0mg 6/50 12/50 23/50 28/50 lun a/a 30.7mg * P<.0005 c 18.4mg 67.9mg 8/50 18/50 22/50 28/50 mey MXA 37.6mg Z P<.0005 20.7mg 76.6mg 0/50 3/50 14/50 (9/50) mey:hem,hes. S mey hes 39.0mg Z P<.0005 21.2mg 81.4mg 0/50 3/50 13/50 (7/50) S liv MXA 39.9mg * P<.009 18.6mg 1.05gm 43/50 38/50 43/50 42/50 liv:hpa,hpb,hpc. S hag MXA 60.9mg * P<.0005 c 33.3mg 172.mg 2/50 5/50 10/50 12/50 hag:ade,anb,car. hag MXA 79.5mg * P<.0005 c 40.4mg 309.mg 2/50 5/50 8/50 10/50 hag:ade,anb. liv hes 123.mg * P<.005 55.7mg 1.30gm 2/50 5/50 6/50 8/50 S sub hes 177.mg * P<.006 73.5mg 2.71gm 1/50 4/50 1/50 7/50 S for MXA 291.mg * P<.008 c 108.mg 7.29gm 1/50 0/50 2/50 5/50 for:sqc,sqp. liv MXA 42.5mg * P<.02 19.4mg n.s.s. 43/50 37/50 42/50 41/50 liv:hpa,hpc. S liv hpa 71.9mg * P<.03 30.1mg n.s.s. 22/50 16/50 19/50 21/50 S kid rua 301.mg * P<.02 108.mg n.s.s. 0/50 1/50 1/50 3/50 S for sqp 335.mg * P<.02 c 114.mg n.s.s. 1/50 0/50 2/50 4/50 TBA MXB 28.4mg * P<.003 14.2mg 182.mg 48/50 48/50 50/50 50/50 liv MXB 39.9mg * P<.009 18.6mg 1.05gm 43/50 38/50 43/50 42/50 liv:hpa,hpb,hpc. lun MXB 17.2mg * P<.0005 11.0mg 31.9mg 13/50 28/50 36/50 43/50 lun:a/a,a/c. 1444 M m b6c inh 24m24 TR467 with step 0 12.1mg 30.4mg 75.9mg kid rua 129.mg * P<.0005 c 65.9mg 327.mg 0/50 2/50 3/50 9/50 1445 R f f34 inh 24m24 TR467 : 0 3.47mg 8.67mg 21.7mg cli MXA 7.14mg Z P<.007 3.30mg 99.4mg 2/50 12/50 (5/50 3/50) cli:ade,anb,car,cnb. S cli MXA 12.4mg Z P<.005 5.01mg 102.mg 0/50 6/50 (4/50 2/50) cli:car,cnb. S ton MXA 32.9mg * P<.0005 18.5mg 83.7mg 0/50 3/50 3/50 11/50 ton:sqc,sqp. S MXA MXA 33.9mg * P<.0005 c 17.9mg 118.mg 1/50 3/50 5/50 11/50 gnv:sqp; orm:sqp; phr:sqc,sqp; ton:sqc,sqp. ton sqp 53.5mg * P<.002 25.9mg 230.mg 0/50 2/50 1/50 7/50 S MXA sqp 61.2mg * P<.007 c 26.5mg 991.mg 1/50 2/50 2/50 7/50 gnv:sqp; orm:sqp; phr:sqp; ton:sqp. MXA sqc 77.8mg * P<.009 c 34.8mg 2.24gm 0/50 1/50 3/50 4/50 phr:sqc; ton:sqc. ton sqc 91.1mg * P<.01 38.8mg 6.01gm 0/50 1/50 2/50 4/50 S mgl fba 16.3mg * P<.03 c 7.18mg n.s.s. 24/50 32/50 36/50 36/50 mgl MXA 20.4mg * P<.07 c 7.90mg n.s.s. 28/50 34/50 36/50 36/50 mgl:car,fba. --- mnl 30.4mg * P<.04 12.3mg n.s.s. 18/50 18/50 20/50 26/50 S thy MXA 113.mg * P<.03 c 41.2mg n.s.s. 1/50 1/50 1/50 5/50 thy:fca,fcc. kid rua 461.mg * P<.06 113.mg n.s.s. 0/50 0/50 0/50 2/50 ubl tcc 467.mg * P<.06 e 115.mg n.s.s. 0/50 0/50 0/50 2/50 MXB MXB 23.3mg * P<.2 8.31mg n.s.s. 30/50 35/50 36/50 36/50 gnv:sqp; mgl:car,fba; orm:sqp; phr:sqc,sqp; thy: fca,fcc; ton:sqc,sqp. C lun a/a 279.mg * P<.2 e 70.2mg n.s.s. 1/50 0/50 0/50 3/50 TBA MXB 25.4mg * P<.3 7.49mg n.s.s. 47/50 50/50 50/50 49/50 liv MXB no dre P=1. n.s.s. n.s.s. 0/50 0/50 0/50 0/50 liv:hpa,hpb,hpc. 1446 R f f34 inh 24m24 TR467 with step 0 3.47mg 8.67mg 21.7mg kid rua 183.mg * P<.006 61.4mg 1.92gm 0/50 0/50 0/50 4/50 S kid MXA 183.mg * P<.006 c 61.4mg 1.92gm 0/50 0/50 0/50 4/50 kid:rua,ruc. 1447 R m f34 inh 24m24 TR467 : 0 2.43mg 6.07mg 15.2mg MXB MXB 5.79mg * P<.0005 3.09mg 13.6mg 2/50 5/50 11/50 18/50 gnv:sqp; lun:a/a,a/c; orm:sqp; phr:sqp; thy:fca, fcc; ton:sqc,sqp. C MXA MXA 10.1mg * P<.0005 c 5.13mg 21.9mg 0/50 2/50 5/50 12/50 gnv:sqp; orm:sqp; phr:sqp; ton:sqc,sqp. MXA sqp 11.1mg * P<.0005 c 5.41mg 27.3mg 0/50 2/50 4/50 10/50 gnv:sqp; orm:sqp; phr:sqp; ton:sqp. ton MXA 13.6mg * P<.0005 6.02mg 35.9mg 0/50 0/50 4/50 8/50 ton:sqc,sqp. S ton sqp 15.6mg * P<.0005 6.39mg 50.6mg 0/50 0/50 3/50 6/50 S thy MXA 18.7mg * P<.003 c 7.52mg 134.mg 0/50 2/50 4/50 5/50 thy:fca,fcc. thy fca 22.0mg * P<.009 7.98mg 1.25gm 0/50 2/50 2/50 4/50 S lun a/c 24.5mg * P<.009 c 9.02mg 961.mg 0/50 2/50 1/50 4/50 --- msm 27.1mg * P<.008 11.6mg 575.mg 0/50 1/50 5/50 3/50 S thy cca 20.0mg * P<.05 6.72mg n.s.s. 3/50 6/50 4/50 7/50 S lun MXA 23.8mg * P<.02 c 8.34mg n.s.s. 2/50 2/50 4/50 6/50 lun:a/a,a/c. kid rua 38.9mg * P<.05 12.4mg n.s.s. 0/50 1/50 1/50 2/50 S MXA sqp 39.2mg * P<.02 15.3mg n.s.s. 0/50 2/50 1/50 4/50 gnv:sqp; orm:sqp; phr:sqp. S ubl tcc 99.9mg * P<.4 e 16.3mg n.s.s. 0/50 0/50 1/50 0/50 ubl tpp 468.mg * P<.2 e 76.2mg n.s.s. 0/50 0/50 0/50 1/50 TBA MXB 6.12mg * P<.04 2.52mg n.s.s. 50/50 50/50 50/50 50/50 liv MXB no dre P=1. n.s.s. n.s.s. 0/50 0/50 0/50 0/50 liv:hpa,hpb,hpc. 1448 R m f34 inh 24m24 TR467 with step 0 2.43mg 6.07mg 15.2mg kid rua 15.4mg * P<.008 c 6.18mg 462.mg 1/50 7/50 6/50 8/50 kid MXA 16.1mg * P<.02 6.26mg n.s.s. 1/50 8/50 6/50 8/50 kid:rua,ruc. S

Mutagenicity in Salmonella: negative
SMILES Code for Chloroprene (>96% chloroprene): C=C(Cl)C=C
InChI Code for Chloroprene (>96% chloroprene): InChI=1/C4H5Cl/c1-3-4(2)5/h3H,1-2H2
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for Chloroprene (>96% chloroprene): Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.


Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (tehip@teh.nlm.nih.gov).
Last updated: October 3, 2007


PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10